Multiple Studies Show hTEE Significantly Changes Patient Management

ImaCor Inc., the developer of the world's only hemodynamic transesophageal echocardiography (hTEE™) technology, announced that multiple recent studies have shown that hTEE significantly changes patient management in critical care.


hTEE provides direct visualization of heart size and function over time, a major advantage compared with conventional hemodynamic monitoring. Researchers from multiple institutions found that conventional assumption-based monitoring often led to inaccuracies in the assessment of cardiac function. hTEE imaging information guided major changes in patient management, including modifications to ventilator and mechanical circulatory support settings; safe, rapid titration of fluid, inotropes and vasopressors; and effective management of the right ventricle (RV).


A multi-center study of 94 patients published in Intensive Care Medicine demonstrated that hTEE made "a direct therapeutic impact in 62 patients (66%)." hTEE also "allowed the confirmation that ongoing treatment was well adapted to the hemodynamic profile" (Vieillard-Baron A, Slama M, Mayo P, et al. Intensive Care Med. 2013; 39:629-35).

 

In the August edition of the Journal of Cardiothoracic & Vascular Anesthesia, a study from Vanderbilt University Medical Center (Nashville) reported that hTEE enabled early identification of RV dysfunction in 33% of a group of complex open heart surgery patients. The authors observed discordance between hTEE and conventional hemodynamic monitoring in 66% of the patients studied (Maltais S, Costello WT, Billings FT 4th, et al. J Cardiothorac Vasc Anesth. 2013; 27:665-9).

 

Additional peer-reviewed findings proving hTEE's significant impact in critical care, including from Charité University Medical Center (Berlin) and Thomas Jefferson University Hospital (Philadelphia), are available at the ImaCor website.

About ImaCor

ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare resources. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™, and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacorinc.com. Follow us on Facebook, Twitter, and YouTube.

Media Contact:

Media Inquiries ImaCor, Inc. | Jennifer D. Kujawski | +1 516 393 0970 | This email address is being protected from spambots. You need JavaScript enabled to view it.